Insmed Inc (INSM)

Currency in USD
131.10
-1.45(-1.09%)
Closed·
130.35-0.75(-0.57%)
·

INSM Earnings

Latest Release
Aug 06, 2026
EPS / Forecast
-0.06 / -0.70
Revenue / Forecast
425.49M / 392.53M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09--/-0.602--/469.97M----Free Sign Up
2026/06-0.060/-0.698425.49M/392.53M+91.41%+8.4%Free Sign Up
2026/03-0.760/-0.960305.96M/301.51M+20.83%+1.48%Free Sign Up
2025/12-1.54/-1.17263.80M/208.20M-31.62%+26.71%Free Sign Up
2025/09-1.75/-1.34142.00M/114.87M-30.6%+23.62%Free Sign Up
2025/06-1.70/-1.30107.40M/103.41M-30.77%+3.86%Free Sign Up
2025/03-1.42/-1.3592.82M/90.78M-5.19%+2.25%Free Sign Up
2024/12-1.32/-1.18104.44M/97.68M-11.86%+6.92%Free Sign Up
2024/09-1.27/-1.2093.42M/93.35M-5.83%+0.07%Free Sign Up
2024/06-1.94/-1.2490.34M/87.95M-56.45%+2.72%Free Sign Up

All numbers in USD

Insmed Inc Earnings Call Summary for Q2/2026

  • Insmed Q2 revenue surged on BRINSUPRI's $309.2M and ARIKAYCE's $116.3M, driving shares up 28.3% premarket to $127.04 from $99.02 close.
  • Company raised 2026 BRINSUPRI guidance to $1.25B-$1.4B from over $1B; increased combined peak sales estimate for three assets to $14B from $8B.
  • BRINSUPRI added 7,000 new patients in Q2, all organic demand; prescriber base grew to 6,300+ with 90% payer approval rate within one week.
  • Insmed expects cash flow positivity in 2027 without additional capital raises; cost of revenues improved to 16% from 26% year-over-year.
  • Japan approval for BRINSUPRI expected H2 2026 with international revenue starting 2027; $50M milestone payment to AstraZeneca due H2 2026.
Last Updated: 2026-08-06, 09:10 a/m
Read Full Transcript

FAQ

What Is Insmed's Earnings Per Share (TTM)?

The Insmed EPS (TTM) is -4.08.

When Is The Next Insmed Earnings Date?

Insmed will release its next earnings report on Oct 22, 2026.

What Is Insmed’s Revenue Forecasts For Upcoming Quarters?

Insmed’s revenue forecast is 469.97M.

How Did Insmed React to the Company's Latest Earnings Report?

Insmed reported a +91.41% EPS surprise and a +8.4% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 32.40%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.